NO2440225T3 - - Google Patents

Info

Publication number
NO2440225T3
NO2440225T3 NO10725159A NO10725159A NO2440225T3 NO 2440225 T3 NO2440225 T3 NO 2440225T3 NO 10725159 A NO10725159 A NO 10725159A NO 10725159 A NO10725159 A NO 10725159A NO 2440225 T3 NO2440225 T3 NO 2440225T3
Authority
NO
Norway
Application number
NO10725159A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2440225T3 publication Critical patent/NO2440225T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
NO10725159A 2009-06-11 2010-06-11 NO2440225T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290437A EP2260857A1 (fr) 2009-06-11 2009-06-11 Nouvelles applications de HIP/PAP ou dérivés associés
PCT/EP2010/058270 WO2010142800A1 (fr) 2009-06-11 2010-06-11 Nouvelles applications de la protéine hip/pap ou de ses dérivés
EP10725159.7A EP2440225B1 (fr) 2009-06-11 2010-06-11 Nouvelles applications de hip/pap ou dérivés associés

Publications (1)

Publication Number Publication Date
NO2440225T3 true NO2440225T3 (fr) 2018-03-17

Family

ID=41478766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10725159A NO2440225T3 (fr) 2009-06-11 2010-06-11

Country Status (17)

Country Link
US (1) US20120142604A1 (fr)
EP (2) EP2260857A1 (fr)
JP (1) JP5836937B2 (fr)
CN (1) CN102625707A (fr)
AU (1) AU2010258565B2 (fr)
CA (1) CA2765180A1 (fr)
DK (1) DK2440225T3 (fr)
ES (1) ES2656353T3 (fr)
HR (1) HRP20180090T1 (fr)
HU (1) HUE036262T2 (fr)
LT (1) LT2440225T (fr)
NO (1) NO2440225T3 (fr)
PL (1) PL2440225T3 (fr)
PT (1) PT2440225T (fr)
SG (1) SG176760A1 (fr)
SI (1) SI2440225T1 (fr)
WO (1) WO2010142800A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
WO2018094398A1 (fr) 2016-11-21 2018-05-24 Mark Evans Système, appareil et procédé destinés à la surveillance et à l'évaluation du niveau de risque fœtal pendant le travail
CN107936111B (zh) * 2017-12-16 2021-09-07 广州安辰新药研究院有限公司 一种hip/pap蛋白的制备方法
CA3119938A1 (fr) * 2018-11-14 2020-05-22 Mark Evans Procede et appareil pour reduire le risque de lesion neurologique neonatale
EP4252766A1 (fr) 2022-04-01 2023-10-04 The Healthy Aging Company Protéine hip/pap ou un de ses dérivés pour le traitement et/ou la prévention d'un trouble caractérisé par un niveau élevé de sérum cxcl5 chez un individu
EP4464330A1 (fr) * 2023-05-17 2024-11-20 The Healthy Aging Company Protéine hip/pap ou un dérivé de celle-ci pour le traitement d'un trouble cognitif associé à un trouble anxieux
IL324576A (en) * 2023-05-17 2026-01-01 The Healthy Aging Company Hip/pap protein or its derivative for the treatment of anxiety-related cognitive disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
WO2001023426A2 (fr) * 1999-09-30 2001-04-05 Varian Associates, Inc. Genes humains et proteines relatifs a l'hypoxie et leurs utilisations
US20030235882A1 (en) * 2000-12-19 2003-12-25 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
EP1478772A2 (fr) * 2001-08-14 2004-11-24 The General Hospital Corporation Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
EP1488798A1 (fr) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composition de polypeptide HIP/PAP pour utilisation dans la régénération du foie et dans la prévention de l'insuffisance hépatique
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
WO2007071437A2 (fr) 2005-12-22 2007-06-28 Ares Trading S.A. Compositions et méthodes pour traiter des troubles inflammatoires

Also Published As

Publication number Publication date
LT2440225T (lt) 2018-02-26
WO2010142800A1 (fr) 2010-12-16
JP2012529475A (ja) 2012-11-22
SG176760A1 (en) 2012-01-30
HUE036262T2 (hu) 2018-06-28
CN102625707A (zh) 2012-08-01
AU2010258565B2 (en) 2016-04-28
SI2440225T1 (en) 2018-05-31
ES2656353T3 (es) 2018-02-26
JP5836937B2 (ja) 2015-12-24
EP2260857A1 (fr) 2010-12-15
DK2440225T3 (en) 2018-01-22
EP2440225A1 (fr) 2012-04-18
EP2440225B1 (fr) 2017-10-18
AU2010258565A1 (en) 2012-01-19
CA2765180A1 (fr) 2010-12-16
PT2440225T (pt) 2018-01-22
US20120142604A1 (en) 2012-06-07
PL2440225T3 (pl) 2018-07-31
HRP20180090T1 (hr) 2018-04-06

Similar Documents

Publication Publication Date Title
BE2015C040I2 (fr)
BR112012008195A2 (fr)
BR112012003062A2 (fr)
BRPI0924307A2 (fr)
BR112012008267A2 (fr)
BR112012012396A2 (fr)
BR112012000607A2 (fr)
BR122021004633A2 (fr)
BR112012000665A2 (fr)
BR112012012487A2 (fr)
BR122017024704A2 (fr)
BR112012003853A2 (fr)
BRPI0924534A2 (fr)
BR112012009797A2 (fr)
BR112012009703A2 (fr)
BR112012001263A2 (fr)
BR112012010357A2 (fr)
BR112012007656A2 (fr)
BR112012000159A2 (fr)
BR112012014856A2 (fr)
BR112012007672A2 (fr)
BR112012000156A2 (fr)
BR112012007671A2 (fr)
BR112012009404A2 (fr)
BRPI0925022A2 (fr)